Seeking Alpha HealthcareOriginal article
Carlsmed outlines $74M-$78M 2026 revenue outlook as CMS finalizes new aprevo lumbar MS-DRGs effective October 1
RegulatoryaprevoPositive
AI Analysis
Summary
Carlsmed provided 2026 revenue guidance of $74M-$78M as CMS finalized new aprevo lumbar MS-DRGs effective October 1, 2026.
Financial Highlights
Guidance
$74M-$78M for 2026
Outcome Details
CMS finalized new aprevo lumbar MS-DRGs effective October 1
Importance:5/10
Sentiment:
0.50
regulatoryCMSDRGrevenue guidance
Read the original article
Published by Seeking Alpha Healthcare on August 6, 2026 12:11 AM